Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AbVacc, Inc. is a biotechnology company pioneering structure-guided vaccine and therapeutic development for emerging infectious diseases. With a strong pipeline targeting bacterial and viral infections, AbVacc focuses on S. aureus virulence factors, including its IBT-V02 vaccine, set for clinical trials in 2024. The company also develops potent antibodies against Ebola, Marburg, and Nipah viruses. Based in Rockville, Maryland,...
AbVacc, Inc. is a biotechnology company pioneering structure-guided vaccine and therapeutic development for emerging infectious diseases. With a strong pipeline targeting bacterial and viral infections, AbVacc focuses on S. aureus virulence factors, including its IBT-V02 vaccine, set for clinical trials in 2024. The company also develops potent antibodies against Ebola, Marburg, and Nipah viruses. Based in Rockville, Maryland, AbVacc collaborates with U.S. government agencies, biotech firms, and academic institutions to advance innovative treatments for global health threats.

List your booth number for exhibitions, ask us